Springer Nature AG & Co. KGaA (SPG) Earnings Call Transcript
August 5, 2026
Earnings Call Speaker Segments
Good day, and thanks for joining us on the Springer Nature investor call covering the first six months of 2026. Please be aware that this session is being recorded. Right now, everyone attending is in listen-only mode. Once the presentation wraps up, we'll open the line for your questions. I'll hand things over now to Tom Waldron, our Head of Investor Relations, who is hosting today.
Thanks, Carissa. Good afternoon, everyone, and welcome to the Springer Nature H1 2026 Results Call. I'm Tom Waldron, Head of Investor Relations. The presentation today will follow this structure. Frank will begin with a business update, and then Alexandra will review our H1 2026 financials, after which we'll go to Q&A. Before I hand over, let me briefly remind you that for revenues and adjusted operating profit, we present figures using actual currency rates and portfolio composition, along with underlying growth rates, which exclude currency and portfolio effects so that the comparison is like-for-like. Our financial guidance for 2026 rests on the expected underlying performance of the business, excluding FX and portfolio changes. Where growth rates come up in this presentation, they are underlying unless otherwise specified. With that, I'll now hand over to Frank.
Thanks, Tom, and a warm welcome from me as well. Let me begin with the highlights. The results demonstrate sustained solid progress, with revenue up 6% on an underlying basis and AOP rising 8%. Research remains our primary growth engine, delivering strong performance throughout our journal portfolios. Once again, growth came from our leadership position in open access plus our investments in technology and AI. We posted another robust cash flow result, with leverage comfortably inside our target range, even following payment of the 2025 EUR 0.83 dividend in June. With such a strong first half and the visibility we have for the rest of the year, we've updated guidance: we now anticipate 2026 underlying growth of around 6%, and we expect the AOP margin to expand by at least 30 basis points in underlying terms. As a reminder, Springer Nature competes in three appealing markets where our positions are strong. As you can see, Research is still far and away our biggest segment, accounting in H1 2026 for almost 80% of group revenue and more than 90% of adjusted operating profit. That speaks to the scale, quality, and resilience of our research portfolio. By a considerable margin, we are the second-largest publisher of academic journals.
When it comes to the top 50 journals measured by impact factor, we hold the biggest share, and we're also the biggest academic book publisher globally. Roughly 60% of the revenue our research business brings in is under contracts that usually run three to five years. Before I move into a business update, I want to share a few recent examples of research from journals across our portfolio. Taken together, these studies illustrate how broad the research ecosystem is that we back. They also demonstrate the difference that trusted, high-quality research can make across disciplines and for society. To start, a paper on their robotic system, Ace, was published by researchers at Sony AI — a system able to beat elite table tennis players in open play. As with most research, this paper came out of several years of effort by the research team. If you follow my LinkedIn profile, you may know that during a visit to Sony's computer science laboratories in Japan last year, I got the chance to have a go at playing Ace. To be clear, I wouldn't describe myself as an elite table tennis player, so I think Ace had an easy time of it there. Still, I managed to win a couple of points. I suppose the robot needed a bit of oiling there, but it was a pretty one-sided match.
That served as a strong illustration of how quickly things are moving and how AI plus robotics are reshaping science. Second, findings appeared in "BMC Microbiome" indicating that the remains of Ötzi, the Iceman, still contain living ancient microbes going back thousands of years, ancient yeasts among them. That work drew a fair amount of press attention, especially once it also came out that the team had grown that 5,000-year-old yeast and baked a loaf of bread with it. Nothing was said about the taste. Third, Scientific Reports carried a paper indicating that diminishing sea ice around Svalbard has, unexpectedly, made polar bears healthier — though the researchers warn this upside could prove short-lived. Over 80% of what we publish contains original primary research insights of the sort seen in these papers. Such verified, trusted knowledge is essential to moving human progress forward. Now let's turn to how our segments performed in the first half, beginning with research. Research put in another strong showing. Revenue rose 7% on an underlying basis, and adjusted operating profit was up 8%. The 2026 renewal season has wrapped up with a retention rate of almost 100%. Growth in our journals portfolio was broad-based across our full open access Nature and Springer portfolios.
Publication growth for our articles came in at 13%, which again beat the market — we estimate that market expanded roughly 8% during the first half. Submissions rose 30%, holding at levels comparable to what we saw a year earlier, and that strength was broad, showing up throughout the portfolio and in every major region. Open access uptake remains a priority we keep pushing forward. We closed 19 fresh transformative agreements, which lifts the cumulative count past 100 and brings more than 4,500 institutions under coverage. In H1 we additionally introduced 39 journals, among them Nature Progress Oncology, Scientific Reviews, BMC Sustainability, and Discover Telecommunications. Even as publication volumes climb, the impact of our portfolio has risen too — close to two-thirds of our journals posted a higher impact factor in Clarivate's JCR report for 2025. Underpinning this journal growth is the AI strategy we set out during our full-year presentation in March and again at our recent Investor Tech event. New journals keep joining SNAPP, our AI-enabled article processing platform. So far this year, more than 60% of submissions have gone through SNAPP. Our journal finder, for instance, draws new authors to Springer Nature, while our AI tools help editors locate suitable reviewers more quickly. And through our transfer recommender, quality papers turned away for scope reasons stay within our ecosystem.
Artificial intelligence tools are assisting our teams in upholding research integrity throughout the portfolio. Manuscript advisor was rolled out to users of Nature Research Assistant, the AI tool we offer to researchers. Feedback keeps coming in that is highly favorable from a sizable pool of beta testers, with customer satisfaction figures comfortably above 80%. As you might have noticed, we announced an ARC3 partnership yesterday. Through these partnerships, researchers, clinicians, and R&D teams can reach our trusted scientific content inside AI-powered environments. They mark the next stage in how our long-standing text and data mining businesses are evolving. In books, revenue was up, with positive phasing in digital products. A milestone that is especially exciting for our books business came in July with the launch of Nature Books, which combines the strength of the Nature brand with our leading position in this market. Research AOP grew more quickly than revenue, reflecting operating leverage and continuing efficiency gains. Last, in H1 we announced the disposal of our consumer media business, which further sharpens our focus on the core Research segment. Let's move now to what happened in our other two segments, Health and Education. Taking Health first. Revenues and AOP both rose by 1%. Growth in revenue was led by the DACH markets. Overall performance reflected a tough comparison in the Netherlands and a challenging climate for pharma marketing spend in international healthcare.
Now on Education: revenue and AOP were up 4%, driven by a strong showing in Southern Africa, with solid growth in Zimbabwe as well. Results there also got a lift from expansion in India and from favorable phasing in Western Europe. We put up a good growth performance in education during H1, even though H1 of last year included the benefit of a sizable government order in Argentina. Before handing things to Alexandra, I want to stop and take a somewhat closer look at one piece of our journals portfolio — our full open access journals. Open access keeps delivering value for researchers, institutions, and funders by boosting visibility, accessibility, and impact. As we've said previously, papers published as open access see 6x more downloads, 1.6x more citations, and attract 5x as much public attention relative to articles that aren't open access. Our market-leading full open access journal portfolio is broad, since it spans every research area, and deep, since it covers all impact factor ranges. It now stands at over 800 journals and keeps growing. Quality metrics across the portfolio continue to improve year-on-year in 2025. We hold roughly 18% article share in full open access, and those articles account for 26% of all citations from full open access articles.
Our portfolio is obviously of the highest quality anywhere in the industry. Now let's look at the individual brands. Within the Nature portfolio sits Nature Communications, an extremely selective and prestigious title that has become the most cited journal globally. Scientific Reports ranks as the largest journal in the world. Its aim is to be inclusive while not sacrificing the rigor of peer review. Roughly 16 years after launching within the Nature portfolio, Scientific Reports has published work from more than 1 million authors. It drew nearly 1.1 million citations last year, placing it second behind only Nat Comms in terms of impact. Between Nat Comms and Scientific Reports sit three portfolios. There are our communications journals. There are our Nature partner journals. And there is our recently launched Nature Progress imprint. Beyond the Nature portfolio lies BMC, started in 2000 as the first commercial open access publisher. Over the last 25 years, BMC has been a pioneer of open access. BMC provides a complete portfolio for biomedical communities, spanning prestigious titles such as BMC Medicine and Molecular Cancer plus a rapidly growing series of inclusive journals. Discover launched in 2020 to serve research communities, especially in applied science fields.
Discover is a young portfolio that's growing strongly. Just in H1, we launched 14 new Discover journals, which takes the total to roughly 80. As we discussed in more detail last quarter, our Springer portfolio contains over 340 full open access journals. Springer led the way on transformative agreements back in 2015 and still pushes OA adoption forward today. And within our Health segment, we have Cureus, a full open access journal built on an innovative model that charges editing fees instead of a traditional APC. We've grown our market-leading full open access portfolio, launching 150 journals since 2024. We've expanded our star footprint in growth markets, and we've capitalized on our investment in technology and AI, and as a result, we have outgrown the industry and continue to do so in H1. With that, I'll pass it to Alexandra for a financial update.
Thanks, Frank. Now I’ll walk you through the financial performance in more detail. We had a strong first half. Revenue came in at EUR 940 million, with underlying growth of 6%. Adjusted operating profit was EUR 246 million, up 8% on an underlying basis. Underlying AOP margin rose by 38 basis points. Free cash flow grew by EUR 64 million to EUR 268 million. That reflects strong operational delivery helped by favorable phasing impacts. Leverage declined further compared with year-end 2025, finishing the half at 1.6x, comfortably inside our target range. These metrics’ consistency shows we can turn strong operational performance into profitable growth and cash generation. The next slide gives further insight into our segments, covering both reported and underlying revenue and adjusted operating profit growth. Frank has already covered the key drivers here. Reported revenue growth was lower, mainly because of currency movements, particularly the stronger euro against the U.S. dollar and Indian rupee, as well as the impact of hyperinflation in Argentina. Underlying AOP margin rose by 38 basis points. The reported margin of 26.2% also reflects a benefit from scope of around 16 basis points. That benefit comes from lower losses at Scientific American before the divestment of that business at the end of June 2026.
The underlying improvement plus the scope benefit got offset by an FX headwind of roughly 33 basis points. That FX headwind was partly mitigated by depreciation of the British pound and the Indian rupee, which brought down our cost base. On top of that, we gained from a favorable quarter and FX revaluation on accounts receivable. Now let's go to adjusted net income. As expected, the very strong operating performance we delivered got offset at the net income and EPS level by normalization of the financial result and tax rate in 2026. The adjusted financial result came in as a net expense of EUR 39.7 million versus EUR 20.7 million in the prior year. The year-on-year movement mainly reflects favorable currency translation effects on intercompany balances in H1 2025, which did not recur this year. That was partly offset by lower leverage and improved borrowing costs. As expected, the adjusted tax rate went up from 24.7% to 31.7%. You may recall that H1 2025 saw a one-off tax benefit related to the utilization of tax losses carry forward. This results in adjusted net income of EUR 141 million and adjusted EPS of EUR 0.71. Turning next to cash. Cash generation was particularly strong in the first half.
Free cash flow rose EUR 64 million to EUR 268 million, helped along by better operating performance and reduced interest payments; H1 free cash flow additionally gained from favorable phasing effects as well as tax, investments, and interest. The drop in interest and fee payments came from both lower average debt levels and lower interest rates. We likewise recorded timing advantages stemming from the 2025 Schuldscheindarlehen, which pushes part of the cash interest out into subsequent quarters. Robust H1 cash generation underpinned ongoing deleveraging, and we closed the half year at 1.6 times net debt to EBITDA, even after distributing more than EUR 160 million in dividends during June. The way we allocate capital has not changed. Funding organic growth, keeping a strong balance sheet, and seeking value accretive M&A opportunities with a strong strategic fit remain our priorities. We keep paying a progressive dividend, and following our 2026 AGM, we can now return excess capital through buybacks going forward. Last, let me move to our guidance. In light of the strong first half performance, we have revised our outlook for full year 2026. We now anticipate underlying revenue growth of around 6%, versus the earlier 5%-6% range, along with underlying improvement in AOP margin of at least 30 basis points.
This FX scenario that's up on the slide is the same one we provided back in March. It relies on FX rates as of the close of full year 2025. Should the dollar strengthen across the rest of 2026, that would give a boost to both revenue and margins, though the effect is also tempered by the fact that roughly 60% of our research revenues are contracted and invoiced at renewal season rates. If euro dollar rates, which stood at 114 at the end of June, were to hold through year-end, the adverse impact would be smaller — roughly 2.6% on revenue growth and around 30 basis points on AOP margin. At the rates we see today, we sit somewhere between those two scenarios. With that, I'll hand it back to Frank to wrap up today's presentation.
Thanks, Alexandra. As you’ve seen, we’re pleased with the strong results we delivered in the first half of 2026, which show the strength of our business—both in financial performance and in executing our strategy. Research is the main force behind that momentum. That comes partly from our leadership in open access and from our commitment to embracing AI across the portfolio. This gives us confidence as we look ahead, and it allows us to update our 2026 outlook, as Alexandra just explained. We’re well-positioned to keep growing sustainably and responsibly in the years ahead as we outperform the industry. With that, I’ll hand it back to Tom for Q&A.
Thanks, Frank. We’re going to move on to Q&A now. Just a reminder that we’re asking every analyst to keep to two questions at the start. If you have more questions after that, we’ll gladly return to you later on. With that said, I’ll turn the call back over to Carissa.
Ladies and gentlemen, should you wish to pose a question, kindly press star nine followed by the pound key on your phone's keypad. To withdraw your question, press star three and then the pound key. Alternatively, you may use the dial-in feature within the webcast and raise your hand if you'd like to ask something over the phone. Our first question comes from Nick Dempsey at Barclays. Nick, the floor is yours.
Good afternoon. I have a couple of questions, please. First, the newest item people in the U.S. have chosen to fret over regarding academic publishing is the OMB decision, and I realize no ruling has come down on that yet. I'm curious whether you could speak a bit about the possible impact if it does in fact go through and federal money can't be spent on subscriptions or APCs, and how you're viewing the matter more broadly? Second, article submission volumes in this market have been quite strong relative to prior periods for a good while now. It doesn't appear probable that this keeps going indefinitely. Looking toward next year, do you believe we should begin anticipating that volume growth will start to normalize, or is that even further out than next year?
Thanks, Nick. Good afternoon. I'll address both questions, and perhaps take the last one first. On submission growth and how we see it: as we mentioned in the presentation, we've observed robust submission growth across the portfolio, at roughly 30%, which continues the trend from the last two years. Looking at the underlying factors, I'd point to two. First — and I think this is an important driver — new regions such as Latin America, along with the Middle East and India, are contributing, let's say, to global article growth. That's number one. Second, we're also seeing an acceleration in research discovery stemming from AI adoption. Against that favorable market momentum, I think we're performing well, and I've just explained why that is. Above all, it's because we have an extremely strong portfolio with Nature, Springer, and our full open access brands, as well as the investments made over the past couple of years. We've broadened our portfolio by launching new journals.
We've grown our presence in the markets seeing the strongest growth, particularly in Asia. We've put money into technology and rolled out collections—so a fair number of initiatives are in place to help drive share gains. If you ask how we view that momentum, at present we aren't seeing any slowdown. Across every region, submission growth remains solid. In fact, in North America and Western Europe, submission growth has actually accelerated. So we don't see a slowdown yet, and we aren't expecting one at this point. Hopefully that covers your second question. Turning to your first one, the OMB, and what should we be thinking there? I think it always helps to keep things in perspective, and it's worth recognizing that ours is a diversified, resilient business. The U.S. represents roughly 25% of revenues and 12% of the articles we publish. Bear in mind that within that 12% of articles we publish, roughly half come from federally funded research. That works out to 6% of the articles we publish.
Second, I think another key point is that researchers at academic institutes actually draw on multiple funding sources to cover APCs and subscriptions. They don't rely solely on federal funds — they use several funding streams for those costs. I think that's the second thing to bear in mind. If you look at the OMB, the Office of Management and Budget, which assists the president in setting the federal budget and provides advice on budget rules and policies, it has proposed some broad changes regarding how policies govern federally funded research. What we saw following the announcement and the 45 days consultation period, which concluded on the 13th of July, was quite an enormous reaction from the research community in the U.S. I think more than 500,000 comments, which by any measure is quite extraordinary, especially considering that most of those comments were genuinely distinct from one another. It wasn't a petition signed by a lot of people, but truly a lot of individual content feedback. At this stage, I think we simply have to wait and see what comes out of that. I think there's not much more to say about that at this point.
The sole point there is that we really don't anticipate any negative effect on our results for this year. That is the reason we've updated our guidance.
Thanks.
I hope that answers your questions. Sorry.
Sure.
Our next question comes from Steve Liechti at Deutsche Bank. Steve, you have the floor.
Yes, hello. My two questions are as follows: could you provide a bit more detail on Nature Research Assistant? I'm asking with the Claude Science launch in mind, since we last spoke, and how it sort of competes with that. Also an update on the monetization model, or your thinking there if there has been any progress. That's the first question. The second one concerns the consumer journals exit. I'm wondering whether, within your portfolio, there's anything else that might be obvious to you that should be obvious to us as a possible further divestment candidate, and whether those journal exits have altered or indicate an alteration in your appetite for, in a sense, consolidating the portfolio further. Thanks.
Thanks a lot, Steve, and good afternoon to everyone. On Nature Research Assistant, I’ll take the first question. Alexandra will cover the portfolio changes. As you’re aware, Nature Research Assistant sits within our broader AI strategy — one focused on changing how publishing works, making research findings more visible, and safeguarding the integrity of the scientific record. For us, I see Nature Research Assistant as a chance to help researchers across a wider range of use cases throughout the researcher workflow. Given our strong Nature brand — which represents integrity and quality across the research community — I believe we’re very well placed to go after that opportunity. We also have access to high-quality content and technology, and what matters a great deal too is our extensive in-house editorial expertise. Looking at where things stand now, we have roughly 25,000 beta users.
Carissa, there’s some noise on the line.
Yes.
Alright, sorry about that. We've got roughly 25,000 beta users.
Folks, this could be on my side. Would you like me to mute myself?
Oh, yeah. That’s better.
All right, that's an improvement.
Thank you.
Alright. I believe Steve, you're on mute at the moment. We're genuinely pleased with the response we're getting. CSAT is comfortably above 80%, and we keep introducing new features. We began with writing and the initial articles, and now we're moving into the Discover area. A commercial launch of Nature Research Assistant is planned for early next year, early 2027. When you consider the monetization approach, I'd say it will combine a B2B model, since that's where the bulk of our current agreements sit today — something that could work as an add-on to those existing agreements. At the same time, we clearly see an opening for a consumer model as well, aimed at individual researchers. That's where things stand today. As I've mentioned before, I don't think it will be without impact on our short-term results, but I believe this is an opportunity we're extremely well-positioned to pursue, which is why we're going after it. I think that leads into the next question you had, Steve, regarding the portfolio changes.
Exactly. Stephen, as you also mentioned, we sold off our consumer magazines during the second half of the year, and then Scientific American followed, plus the Spektrum deal right at the end of July. Those are strong, well-respected brands, but consumer media hasn't been a central part of Springer Nature's strategic focus, and the synergies with the remainder of our portfolio were limited. Following that divestment, we're now increasingly concentrated on research, where we see appealing growth opportunities fueled by open access, technology, and AI. We'll keep reviewing our portfolio on an ongoing basis, and our main priority will stay creating shareholder value through organic growth, value accretive M&A, and active portfolio management as well. I hope that addresses your question. Steve is still muted.
Okay, Carissa, could we have Steve’s line unmuted for a moment?
Conor O'Shea from Kepler Cheuvreux has a question. Conor?
Yes, thank you. I have two questions as well. First, I believe you announced a licensing deal with OpenEvidence last night. Could you perhaps provide a bit more detail on that and the rationale behind it, and whether that might make any noticeable difference to adjusted operating profit on a full-year basis next year? Then the second question is maybe for Alexandra, just on net financial costs. I think it came in just under EUR 40 million in the first half of the year. Just for the full year 2026, we'll be thinking double or almost double that for the full year, or maybe a bit less in the second half of the year. Thank you.
On the technology side, our belief is that AI is going to benefit research. We want to be certain — and I think this is ultimately why people choose to publish with us — that we fully capitalize on AI tools, while also giving research findings the greatest possible visibility. I've referenced our AI strategy earlier on this call. ARC3 is part of that strategy, ensuring researchers achieve maximum visibility. At the same time, we naturally recognize that for AI to work properly, it requires trusted content. ARC3 is essentially our AI data licensing solution. It represents a logical extension of the text and data mining business we run, and it rests on a set of principles we have laid out previously as well. Attribution, provenance, and, naturally, a subscription revenue model. We're genuinely very pleased about the agreement recently announced with OpenEvidence, since it truly aligns with the principles we have established. In essence, it guarantees that new medical research insights — and bear in mind that we rank among the largest medical research publishers globally — are delivered at the point of care, and it guarantees clear attribution and provenance for our content.
Naturally, since this operates on a subscription basis, it generates recurring revenue. That said, just because it's a subscription model, so to speak, that doesn't guarantee a big near-term effect, since we're already well into the year — I wouldn't anticipate much of an effect on, say, this year's revenues. Naturally, it will contribute to growth in the following year.
Sure, Conor — I'll handle the question on financial results. For the first half of this year, we've got approximately EUR 20 million approved, versus the same period a year ago, and two main factors are driving that. First, thanks to lower debt and better financing costs, our interest expense came in about EUR 14 million lower — that's one piece of it. Second, last year we had a one-off benefit from a positive valuation impact on our intercompany balances. That was really more of a one-time item last year, and this year we've also put measures in place to bring intercompany balances down further and to optimize our hedging in that regard. We expect less volatility this year than what we saw last year. On interest expense, that's then the main factor you'll also see reflected in financial results — I'd expect an improvement, roughly based on where our debt level stands right now and on the improvements we've seen in base rates as well as our margins. For the full year, I'd roughly expect interest expense to be EUR 20 million lower than what you saw last year.
All right, that's great. Thanks a lot.
Thanks. We’ll take the next question from James Tate at Goldman Sachs. James, go ahead—you have the floor.
Thanks very much. Good afternoon, Frank and Alexandra. This is James Tate calling from Goldman. I have a couple of questions, if I may. First, building on the OpenEvidence deal and looking at it through the ARC3 framework, could you say something about what the pipeline looks like for additional agreements? Should we be expecting further deals of this kind to appear before the year is out? Second, returning to capital allocation: with free cash flow generation coming in strong and de-leveraging likely to take us toward the lower end of the target leverage range next year, how do you intend to keep the balance sheet efficient? Might there be a shift in how you approach M&A, or would a share buyback perhaps be something you'd consider? I'd be keen to hear your thinking on that. Thank you.
Okay, James — for the first question, let me begin with the ARC3 pipeline. I don't think this should come as a surprise. Quite a few companies, let's say, have shown interest in our content, since we're the biggest by a mile and, in terms of journals, the second largest by some distance compared with number three, four, and five. It's obvious that companies genuinely want to partner with us. That said, our requirements and expectations are pretty clear. Yes, a pipeline exists, but I also have to note that getting these deals closed can take a while. I wouldn't count on a significant revenue impact this year from AI licensing. As I said earlier, it's a subscription model, and the later in the year you get, the smaller the impact you'll see.
Alright, picking back up on the leverage and cash flow question. And for the whole year, I do expect cash flow to be strong as well. Our capital allocation priorities are clear, and we'll stay with them. I believe Olaf touched on this during the presentation. The first one for us — and this remains the top priority we keep pursuing — is investing organically in the business, and we still see a number of opportunities there. Maintain that strong balance sheet, but at the same time keep screening the market for M&A that's value accretive. That could involve expanding our portfolio, could be AI, technology we can leverage. All of those topics stay on our radar. We'll keep paying a progressive dividend. Then we think about returning any excess cash. And as I've said on other calls before, we still see benefits from our reduced interest margins. That remains an opportunity for us to bring it down further. On top of that, the leverage we see right now also puts us in a very good position for any refinancing down the road.
That's very clear. Thank you.
David Nolan with Morgan Stanley — you have the next question.
Thanks, guys. My first question is about SNAPP. Over 60% of submissions were processed on SNAPP in H1, which is clearly great progress. I'm just wondering how much of a revenue and margin tailwind we could expect over the next one to two years as the remaining journals are onboarded onto SNAPP. Second, on margin potential, it would be great to get some additional color on the difference between gross margin expansion and underlying margin expansion — and by that I mean what's simply being reinvested back into the business. Getting a better understanding of the quantum of that investment would be very helpful. Thank you.
Yeah.
Alright, I'll take both of those. David, let me begin with SNAPP. You're correct — reaching the point where 60% of our submissions now run on SNAPP is, I believe, a substantial move forward for us, and the benefits come in two distinct ways. First, it's our own proprietary workflow system at this stage, which assists us in reducing costs — previously we also relied on an outside service provider and paid on a per submission basis. There's also cost avoidance involved, since as we grow we keep expanding those submissions, and the costs I just described don't apply. Beyond that, SNAPP genuinely serves as a key differentiator for us through this work tool, with which we aim to deliver a frictionless experience when publishing with us. That covers, on one side, the author's experience, where we're also seeing excellent CSAT. On the other side, it helps us streamline the process of adding new tools that assist us — for instance, in identifying peer reviewers in a faster, more effective manner. It's about adding tools that perform initial checks on submissions — checking quality, checking master data, and so forth.
Every bit of that is pushing us toward what we refer to as the frictionless publishing experience. That is a journey we'll keep moving forward on. As for your question about how this affects our margin — yes, it does make us more efficient. It comes down to that cost avoidance factor. We never discuss our margin in terms of how a given initiative will translate into margin improvement. As you know, in our case, margin development gets looked at on a blended basis. On one hand, we're driving revenue growth, and that also assists us on the product mix side to affect the margin. Then there's the operating leverage that's built into our business. Meanwhile, we put money back into the business, whether that's through further broadening the portfolio — you've seen the 39 journals we launched this year — or through additional investment in technology. What I can say plainly is that we are genuinely committed to growing our AOP faster than revenue, and over time that will lead to further margin improvements. Second, and I believe this was partly addressed already through what I said about SNAPP — you were looking to see the distinction in underlying group margin expansion as well-
The expansion within it.
Regarding that—
Regarding the investment we are making, in terms of what shows up in the P&L.
Yes, that was actually covered in the first question — we take a blended view there, and we won't get into individual initiatives or what their precise effect on our P&L is. As I mentioned earlier, I'd say the ongoing expansion of AOP margin ahead of revenue reflects the underlying steering approach we apply to our business.
I'd say that's a fair point, particularly when you consider, say, the journals we've introduced — those tend to be longer-term investments, and naturally they come at the cost of margin improvement. That said, it has enabled us to grow faster than the market. We're essentially working to strike the right balance.
Right.
First, better margins, and at the same time, making sure we’re set up for growth over the long term.
Thanks a lot. Appreciate it.
Moving on, our next question comes from Konrad Zomer at ABN AMRO. Go ahead, please.
Hello there, and good afternoon. Thank you for taking my questions. My first question concerns your full open access development. I realize you don’t provide a detailed breakdown of revenue growth, but could you indicate what the overall growth of your open access revenues was during the first half? My second question is whether you can update us on how the search for a new finance director is progressing. Thank you.
Konrad, I’ll take both of those questions. On the first one, about growth in full open access: as I said earlier, across the portfolio we’ve recorded 30% growth in submissions and 13% growth in articles, which continues the pattern we saw in 2024 and 2025. When you break that down by portfolio segment, full open access comes in well above that average. Subscription typically sits at or below it, and then there’s also a gap between growth in the Nature portfolio and growth in the Springer portfolio. To put it briefly and get to the key point: full open access runs well above that 30% submission growth and 13% article growth. That reflects two things: we hold a market-leading full open access portfolio, both in quantity and, as I showed, in quality, and we have made those investments. Turning to progress on the search for a new CFO, actually this is probably, Alexandra, your last-
This is my final question.
This is the earnings call for Springer Nature. Once again, I want to express my appreciation for all the effort you have put in during the past two years. At times it has certainly felt like more than two years, particularly when you consider all the work we did surrounding the IPO. Alexandra will be departing by the end of September. We are in a fairly good position — I can say that within the next two to three weeks, we would expect to be able to announce a successor to Alexandra, who will have big shoes to fill. Yes.
Okay, thanks.
Will Packer from BNPP, you're up next. Will?
Hello there. Thank you very much for the question. I'd like to return to the OMB proposals. I believe you said that 6% of your article volumes receive federal funding. If we assumed those OMB rules took effect as scheduled in October, my understanding is that the effect on APC fees would be felt right away. Institutions would need to locate alternative sources of funding, which I'm confident they do for the more prestigious journals, though maybe not as much for the less prestigious ones. Could you say a little about how that would flow through into subscription contracts? From what I understand, having looked at the OMB proposals, that kind of chargeback ability would be diminished. In practice, do you think that would serve as a brake on negotiations over subscription fee inflation, or do you think other areas of the materials budget would be deprioritized? Any color on that would be helpful. Thank you.
Thanks, Will. I’m glad to take a shot at your question. To begin with, I believe entering into hypothetical situations is usually somewhat risky. Let’s wait and see what emerges from this, and as I’ve mentioned, our guidance for this year incorporates our expectations, which is the reason we updated that guidance. The 6% figure you brought up relates, of course, to research funded by the U.S. federal government. I’ve also noted that when we conduct research examining how authors actually cover APCs, they draw on multiple funding sources. It’s important to remember that this 6% covers articles throughout our entire portfolio, at varying APC levels. At this point, we don’t know whether, when, or in what manner, and which parts of the 400-page document containing a large number of guidelines will be put into effect, nor what the consequences will be. Right now, the wisest approach is to observe what results from it. The fact that 500,000 responses to the guidelines have been received is, in my view, genuinely encouraging. We shouldn’t overlook that APCs and subscriptions are not the only matters involved—there is a broad array of different guidelines that would, for example, also affect U.S. societies. That should not be underestimated.
On the APCs, I think we’ll have to wait and see — it’s too early to say. If you look at subscription spend, the impact is even more complicated, because there isn’t necessarily a direct relationship. In the past, we saw proposals about how much overhead could be charged on top of funds. There, too, what was initially announced ended up being quite different from what ultimately happened. Another thing to keep in mind is that we operate in a contracted business. In the U.S., most of our subscription content is actually multi-year, and we’re in the middle of renewal season right now, and so far things are tracking in line with expectations. It’s difficult to say what if, how, what happens, but at this stage, I think we’ll just have to see and wait for what comes out of the whole process.
Appreciate the detail. What's the expected timing for the next update from OMB?
If I had that answer, I believe I'd have shared it with you. At this point, I don't think anyone has it.
Thanks a lot.
Carissa, it doesn't look like there are any further questions waiting in the queue.
That was the final question, folks. You can end the call now.
I appreciate that.
All right, well, I simply want to express our appreciation to everyone for giving us another hour of your time, and I hope the rest of your day is pleasant. Thanks so much.
Thank you, everyone.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Springer Nature AG & Co. KGaA transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Springer Nature AG & Co. KGaA earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.